Up-regulation of MiR-146a Increases the Sensitivity of Non-small Cell Lung Cancer to DDP by Downregulating Cyclin J

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2017 Feb 17

PMID 28202053

Citations 30

Authors

Lin Shi

Zhaozhong Xu

Gang Wu

Xiaoting Chen

Yuanyuan Huang

Yanjing Wang

Weiqiang Jiang

Bin Ke

Affiliations

Soon will be listed here.

Abstract

Background: Cisplatin (DDP)-based chemotherapy is the common first-line therapy for lung cancer. However, their efficacy is often limited by primary drug resistance and/or acquired drug resistance. The aim of this study was to investigate the function of miRNA-146a (miR-146a) in DDP-resistant non-small cell lung cancer (NSCLC), as well as the underlying mechanisms.

Methods: The effect of overexpression of miR-146a and/or knockdown of cyclin J (CCNJ) in A549/DDP and SPC-A1/DDP cells were investigated as follows. The cellular sensitivity to DDP, cell apoptosis, cell cycle and cell mobility were detected by CCK-8, flow cytometry, hoechst staining and cell invasion/migration assay, respectively. The effects of miR-146a overexpression in NSCLC resistant cells were further analyzed in a nude mouse xenograft model.

Results: Overexpression of miR-146a and/or knockdown of CCNJ significantly increased the sensitivity to DDP in A549/DDP and SPC-A1/DDP cells compared to NC group via arresting cell cycle, enhancing cell apoptosis, inhibiting cell viability and motility in vitro and in vivo. Furthermore, miR-146a could specially degrade the mRNA of CCNJ, as examined by dual luciferase report assay.

Conclusion: The study indicates a crucial role of miR-146a in the development of acquired drug resistance to DDP in NSCLC cells. Further understanding of miR-146a mediated crosstalk networks may promote the clinical use of miR-146a analogue in NSCLC therapy.

Citing Articles

Transcriptomic-Based Identification of miR-125a Novel Targets in Human Hepatocarcinoma Cells.

De Leo I, Mosca N, Pezzullo M, Valletta D, Manfrevola F, Mele V Biomolecules. 2025; 15(1).

PMID: 39858538 PMC: 11763984. DOI: 10.3390/biom15010144.

Exosomal microRNAs in lung cancer: a narrative review.

Zhang Z, Lin F, Wu W, Jiang J, Zhang C, Qin D Transl Cancer Res. 2024; 13(6):3090-3105.

PMID: 38988916 PMC: 11231775. DOI: 10.21037/tcr-23-2319.

The Effect of MiR320a on Lung Cancer.

Hasani A Microrna. 2024; 13(3):167-174.

PMID: 38963099 DOI: 10.2174/0122115366296148240530072346.

MiRNA-146a-A Key Player in Immunity and Diseases.

Gilyazova I, Asadullina D, Kagirova E, Sikka R, Mustafin A, Ivanova E Int J Mol Sci. 2023; 24(16).

PMID: 37628949 PMC: 10454149. DOI: 10.3390/ijms241612767.

Emerging role of non-coding RNAs in resistance to platinum-based anti-cancer agents in lung cancer.

Mondal P, Meeran S Front Pharmacol. 2023; 14:1105484.

PMID: 36778005 PMC: 9909610. DOI: 10.3389/fphar.2023.1105484.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Krol J, Loedige I, Filipowicz W . The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010; 11(9):597-610. DOI: 10.1038/nrg2843. View

He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S . The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2005; 102(52):19075-80. PMC: 1323209. DOI: 10.1073/pnas.0509603102. View

Kim E . Chemotherapy Resistance in Lung Cancer. Adv Exp Med Biol. 2015; 893:189-209. DOI: 10.1007/978-3-319-24223-1_10. View

Sui C, Meng F, Li Y, Jiang Y . miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression. J Transl Med. 2015; 13:132. PMC: 4417300. DOI: 10.1186/s12967-015-0488-y. View

Li J, Wang Y, Song Y, Fu Z, Yu W . miR-27a regulates cisplatin resistance and metastasis by targeting RKIP in human lung adenocarcinoma cells. Mol Cancer. 2014; 13:193. PMC: 4158130. DOI: 10.1186/1476-4598-13-193. View

Janikova M, Zizkova V, Skarda J, Kharaishvili G, Radova L, Kolar Z . Prognostic significance of miR-23b in combination with P-gp, MRP and LRP/MVP expression in non-small cell lung cancer. Neoplasma. 2016; 63(4):576-87. DOI: 10.4149/neo_2016_411. View

Moitra K, Im K, Limpert K, Borsa A, Sawitzke J, Robey R . Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One. 2012; 7(9):e45268. PMC: 3445463. DOI: 10.1371/journal.pone.0045268. View

Rosell R, Lord R, Taron M, Reguart N . DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer. 2002; 38(3):217-27. DOI: 10.1016/s0169-5002(02)00224-6. View

10.

Wang X, Tang S, Le S, Lu R, Rader J, Meyers C . Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One. 2008; 3(7):e2557. PMC: 2438475. DOI: 10.1371/journal.pone.0002557. View

11.

Chen X, Jiang Y, Huang Z, Li D, Chen X, Cao M . miRNA-378 reverses chemoresistance to cisplatin in lung adenocarcinoma cells by targeting secreted clusterin. Sci Rep. 2016; 6:19455. PMC: 4725983. DOI: 10.1038/srep19455. View

12.

Harvey R, Mullighan C, Wang X, Dobbin K, Davidson G, Bedrick E . Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood. 2010; 116(23):4874-84. PMC: 3321747. DOI: 10.1182/blood-2009-08-239681. View

13.

Li L, Chen X, Li Y . MicroRNA-146a and human disease. Scand J Immunol. 2010; 71(4):227-31. DOI: 10.1111/j.1365-3083.2010.02383.x. View

14.

Li H, Xie S, Liu M, Chen Z, Liu X, Wang L . The clinical significance of downregulation of mir-124-3p, mir-146a-5p, mir-155-5p and mir-335-5p in gastric cancer tumorigenesis. Int J Oncol. 2014; 45(1):197-208. DOI: 10.3892/ijo.2014.2415. View

15.

Shi Y, Lu J, Zhou J, Tan X, He Y, Ding J . Long non-coding RNA Loc554202 regulates proliferation and migration in breast cancer cells. Biochem Biophys Res Commun. 2014; 446(2):448-53. DOI: 10.1016/j.bbrc.2014.02.144. View

16.

Judson I, Kelland L . New developments and approaches in the platinum arena. Drugs. 2000; 59 Suppl 4:29-36; discussion 37-8. DOI: 10.2165/00003495-200059004-00004. View

17.

Li J, Luo N, Zhong M, Xiao Z, Wang J, Yao X . Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line. Tumour Biol. 2015; 37(2):2387-94. DOI: 10.1007/s13277-015-4017-7. View

18.

Oliver T, Mercer K, Sayles L, Burke J, Mendus D, Lovejoy K . Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev. 2010; 24(8):837-52. PMC: 2854397. DOI: 10.1101/gad.1897010. View

19.

Sun Q, Zhao X, Liu X, Wang Y, Huang J, Jiang B . miR-146a functions as a tumor suppressor in prostate cancer by targeting Rac1. Prostate. 2014; 74(16):1613-21. DOI: 10.1002/pros.22878. View

20.

Ambros V . The functions of animal microRNAs. Nature. 2004; 431(7006):350-5. DOI: 10.1038/nature02871. View